$CMPX
Compass Therapeutics, Inc.

2021 Q4 Form 10-Q Financial Statement

#000095017021004267 Filed on November 12, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2020 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.427M $2.700M $5.291M
YoY Change -3.3% -48.97% 120.46%
% of Gross Profit
Research & Development $9.574M $3.154M $3.670M
YoY Change 117.1% -14.06% -38.63%
% of Gross Profit
Depreciation & Amortization $124.0K $100.0K $400.0K
YoY Change -88.4% -75.0% -20.0%
% of Gross Profit
Operating Expenses $13.00M $5.854M $8.961M
YoY Change 63.53% -34.67% 6.93%
Operating Profit -$5.854M -$8.961M
YoY Change -34.67%
Interest Expense -$35.00K $78.00K $212.0K
YoY Change -78.13% -63.21% -251.43%
% of Operating Profit
Other Income/Expense, Net -$121.0K -$189.0K
YoY Change -35.98%
Pretax Income -$12.99M -$5.975M -$9.150M
YoY Change 54.86% -34.7% 7.27%
Income Tax -$13.00K $0.00 $0.00
% Of Pretax Income
Net Earnings -$12.98M -$5.975M -$9.150M
YoY Change 54.7% -34.7% 7.02%
Net Earnings / Revenue
Basic Earnings Per Share -$0.10
Diluted Earnings Per Share -$150.1K -$96.85K -$179.6K
COMMON SHARES
Basic Shares Outstanding 98.03M 61.69M 52.15M
Diluted Shares Outstanding

Balance Sheet

Concept 2021 Q4 2021 Q3 2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $144.5M $25.51M $55.52M
YoY Change 206.98% -54.05%
Cash & Equivalents $144.5M $25.50M $55.78M
Short-Term Investments $0.00
Other Short-Term Assets $2.591M $3.063M $2.314M
YoY Change -17.11% 32.37%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $147.1M $28.57M $57.83M
YoY Change 193.03% -50.59%
LONG-TERM ASSETS
Property, Plant & Equipment $2.243M $1.435M $2.418M
YoY Change 99.2% -40.65%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $320.0K $320.0K $440.0K
YoY Change 0.0% -27.27%
Total Long-Term Assets $6.652M $6.327M $2.858M
YoY Change 289.23% 121.38%
TOTAL ASSETS
Total Short-Term Assets $147.1M $28.57M $57.83M
Total Long-Term Assets $6.652M $6.327M $2.858M
Total Assets $153.8M $34.90M $60.69M
YoY Change 196.19% -42.5%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $867.0K $868.0K $854.0K
YoY Change -18.28% 1.64%
Accrued Expenses $8.775M $1.998M $1.358M
YoY Change 458.56% 47.13%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $3.744M $7.461M
YoY Change -100.0% -49.82%
Total Short-Term Liabilities $10.63M $7.683M $9.673M
YoY Change 5.27% -20.57%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $3.730M
YoY Change -100.0% -100.0%
Other Long-Term Liabilities $3.048M $3.328M
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $3.730M
YoY Change -100.0% -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $10.63M $7.683M $9.673M
Total Long-Term Liabilities $0.00 $0.00 $3.730M
Total Liabilities $13.68M $11.01M $13.40M
YoY Change 14.32% -17.85%
SHAREHOLDERS EQUITY
Retained Earnings -$233.6M -$220.6M
YoY Change 54.28%
Common Stock $373.7M $244.5M
YoY Change 95.28%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $140.1M $23.89M $47.29M
YoY Change
Total Liabilities & Shareholders Equity $153.8M $34.90M $60.69M
YoY Change 196.19% -42.5%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2020 Q3
OPERATING ACTIVITIES
Net Income -$12.98M -$5.975M -$9.150M
YoY Change 54.7% -34.7% 7.02%
Depreciation, Depletion And Amortization $124.0K $100.0K $400.0K
YoY Change -88.4% -75.0% -20.0%
Cash From Operating Activities -$4.665M -$3.457M -$7.169M
YoY Change -29.03% -51.78% 7.0%
INVESTING ACTIVITIES
Capital Expenditures -$777.0K -$367.0K -$7.000K
YoY Change 836.14% 5142.86% -123.33%
Acquisitions
YoY Change
Other Investing Activities $1.000K $0.00 $0.00
YoY Change -98.88%
Cash From Investing Activities -$776.0K -$367.0K -$7.000K
YoY Change -13033.33% 5142.86% -76.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 124.2M -1.875M -2.677M
YoY Change -6725.92% -29.96%
NET CHANGE
Cash From Operating Activities -4.665M -3.457M -7.169M
Cash From Investing Activities -776.0K -367.0K -7.000K
Cash From Financing Activities 124.2M -1.875M -2.677M
Net Change In Cash 118.8M -5.699M -9.853M
YoY Change -1507.19% -42.16% 46.4%
FREE CASH FLOW
Cash From Operating Activities -$4.665M -$3.457M -$7.169M
Capital Expenditures -$777.0K -$367.0K -$7.000K
Free Cash Flow -$3.888M -$3.090M -$7.162M
YoY Change -40.09% -56.86% 6.42%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Entity Central Index Key
EntityCentralIndexKey
0001738021
dei Amendment Flag
AmendmentFlag
false
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39696
dei Entity Registrant Name
EntityRegistrantName
COMPASS THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-4876496
dei Entity Address Address Line1
EntityAddressAddressLine1
80 Guest St.
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 601
dei Entity Address City Or Town
EntityAddressCityOrTown
Boston
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02135
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
500-8099
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
dei Trading Symbol
TradingSymbol
CMPX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
98031565
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
25509000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
47076000
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3063000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3126000
CY2021Q3 us-gaap Assets Current
AssetsCurrent
28572000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-306000
us-gaap Interest Paid Net
InterestPaidNet
226000
us-gaap Interest Paid Net
InterestPaidNet
686000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
0
cmpx Noncash Or Part Noncash Deferred Offering Costs Included In Accrued Expenses
NoncashOrPartNoncashDeferredOfferingCostsIncludedInAccruedExpenses
0
cmpx Noncash Or Part Noncash Deferred Offering Costs Included In Accrued Expenses
NoncashOrPartNoncashDeferredOfferingCostsIncludedInAccruedExpenses
-116000
cmpx Noncash Or Part Noncash Conversion Of Preferred Units
NoncashOrPartNoncashConversionOfPreferredUnits
0
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
194000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
427000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
50202000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1435000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1126000
CY2021Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
210000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
263000
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4362000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
0
CY2021Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
320000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
320000
CY2021Q3 us-gaap Assets
Assets
34899000
CY2020Q4 us-gaap Assets
Assets
51911000
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
868000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1061000
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1998000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1571000
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1073000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
0
CY2021Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
3744000
CY2020Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
7467000
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
7683000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10099000
CY2021Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
0
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1867000
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3328000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0
CY2021Q3 us-gaap Liabilities
Liabilities
11011000
CY2020Q4 us-gaap Liabilities
Liabilities
11966000
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
62323000
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
52117000
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
61760000
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
51221000
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
6000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
5000
CY2021Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
244490000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
191348000
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-121000
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-189000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-220608000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-151408000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
23888000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
39945000
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
34899000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
51911000
CY2021Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
3154000
CY2020Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
3670000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
10763000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
10498000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2700000
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5291000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7500000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9364000
CY2021Q3 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0
CY2020Q3 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
50618000
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
5854000
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
8961000
us-gaap Operating Expenses
OperatingExpenses
68881000
us-gaap Operating Expenses
OperatingExpenses
19862000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5854000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-8961000
us-gaap Operating Income Loss
OperatingIncomeLoss
-68881000
us-gaap Operating Income Loss
OperatingIncomeLoss
-19862000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1215000
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5975000
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-9150000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-69187000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-21077000
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
13000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
32000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-5975000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-9150000
us-gaap Net Income Loss
NetIncomeLoss
-69200000
us-gaap Net Income Loss
NetIncomeLoss
-21109000
CY2021Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.10
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.18
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.26
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.88
CY2021Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
61694000
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
50940000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
55003000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2536000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
23968000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
39945000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
948000
CY2021Q1 cmpx Net Loss
NetLoss
-7422000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
33471000
CY2021Q2 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
50300000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
908000
CY2021Q2 cmpx Net Loss
NetLoss
-55804000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
28875000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
987000
CY2021Q3 cmpx Net Loss
NetLoss
-5975000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
23888000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-118603000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
247000
CY2020Q1 cmpx Net Loss
NetLoss
-6402000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-124758000
CY2020Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
129870000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
6902000
CY2020Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
53581000
CY2020Q2 cmpx Payment To Non Participating Members Upon Consummation Of Merger
PaymentToNonParticipatingMembersUponConsummationOfMerger
-69000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
183000
CY2020Q2 cmpx Net Loss
NetLoss
-5557000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
53250000
CY2020Q3 us-gaap Deferred Finance Costs Ownshare Lending Arrangement Issuance Costs Adjustment
DeferredFinanceCostsOwnshareLendingArrangementIssuanceCostsAdjustment
651000
CY2020Q3 cmpx Net Loss
NetLoss
-9150000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
47287000
us-gaap Profit Loss
ProfitLoss
-69200000
us-gaap Profit Loss
ProfitLoss
-21109000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
442000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1335000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
75000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-8000
cmpx Non Cash Interest Expense
NonCashInterestExpense
35000
cmpx Non Cash Interest Expense
NonCashInterestExpense
72000
us-gaap Share Based Compensation
ShareBasedCompensation
2843000
us-gaap Share Based Compensation
ShareBasedCompensation
2966000
us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
50618000
us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
0
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
0
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-556000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
786000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
0
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-63000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1379000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-25000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-193000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1848000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-747000
us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
0
us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
-1050000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15001000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20230000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
791000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
23000
cmpx Payments For Asset Acquisition Costs
PaymentsForAssetAcquisitionCosts
318000
cmpx Payments For Asset Acquisition Costs
PaymentsForAssetAcquisitionCosts
0
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
115000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
55000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-994000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
32000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
60482000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
6319000
us-gaap Repayments Of Debt
RepaymentsOfDebt
5625000
us-gaap Repayments Of Debt
RepaymentsOfDebt
3750000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-5625000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
50413000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-21620000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
30215000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
47339000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
25566000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
25719000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
55781000
cmpx Noncash Or Part Noncash Conversion Of Preferred Units
NoncashOrPartNoncashConversionOfPreferredUnits
129870000
cmpx Non Cash Or Part Non Cash Payment To Non Participating Investors Within Accrued Expenses
NonCashOrPartNonCashPaymentToNonParticipatingInvestorsWithinAccruedExpenses
0
cmpx Non Cash Or Part Non Cash Payment To Non Participating Investors Within Accrued Expenses
NonCashOrPartNonCashPaymentToNonParticipatingInvestorsWithinAccruedExpenses
-69000
cmpx Noncash Or Part Noncash Right Of Use Asset Acquired Through Operating Leases
NoncashOrPartNoncashRightOfUseAssetAcquiredThroughOperatingLeases
5148000
cmpx Noncash Or Part Noncash Right Of Use Asset Acquired Through Operating Leases
NoncashOrPartNoncashRightOfUseAssetAcquiredThroughOperatingLeases
0
cmpx Noncash Or Part Noncash Acquisition Of Business
NoncashOrPartNoncashAcquisitionOfBusiness
50300000
cmpx Noncash Or Part Noncash Acquisition Of Business
NoncashOrPartNoncashAcquisitionOfBusiness
0
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2018-03-20
us-gaap Proceeds From Sale Of Available For Sale Securities Equity
ProceedsFromSaleOfAvailableForSaleSecuritiesEquity
132000000.0
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
15000000.0
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
25500000
us-gaap Depreciation
Depreciation
1300000
CY2021Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
6337000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7061000
CY2021Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4902000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5935000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1435000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1126000
CY2021Q3 us-gaap Depreciation
Depreciation
100000
CY2020Q3 us-gaap Depreciation
Depreciation
400000
us-gaap Depreciation
Depreciation
400000
CY2021Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
3744000
CY2020Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
7467000
CY2021Q3 cmpx Long Term Debt Before Unamortized Discount Noncurrent
LongTermDebtBeforeUnamortizedDiscountNoncurrent
0
CY2020Q4 cmpx Long Term Debt Before Unamortized Discount Noncurrent
LongTermDebtBeforeUnamortizedDiscountNoncurrent
1875000
CY2021Q3 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
799000
CY2020Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
976000
CY2021Q3 cmpx Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
734000
CY2020Q4 cmpx Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
212000
CY2021Q3 cmpx Leasehold Improvements Current
LeaseholdImprovementsCurrent
320000
CY2020Q4 cmpx Leasehold Improvements Current
LeaseholdImprovementsCurrent
0
CY2021Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
75000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
326000
CY2021Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
70000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
57000
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1998000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1571000
CY2021Q3 cmpx Long Term Debt Before Unamortized Discount Current
LongTermDebtBeforeUnamortizedDiscountCurrent
3750000
CY2020Q4 cmpx Long Term Debt Before Unamortized Discount Current
LongTermDebtBeforeUnamortizedDiscountCurrent
7500000
CY2021Q3 us-gaap Debt Instrument Unamortized Discount Current
DebtInstrumentUnamortizedDiscountCurrent
6000
CY2020Q4 us-gaap Debt Instrument Unamortized Discount Current
DebtInstrumentUnamortizedDiscountCurrent
33000
CY2021Q3 us-gaap Debt Instrument Unamortized Discount Noncurrent
DebtInstrumentUnamortizedDiscountNoncurrent
0
CY2020Q4 us-gaap Debt Instrument Unamortized Discount Noncurrent
DebtInstrumentUnamortizedDiscountNoncurrent
8000
CY2021Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
0
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1867000
cmpx Number Of Operating Lease
NumberOfOperatingLease
1
CY2021Q3 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P4Y5M
CY2021Q3 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.0625
CY2021Q3 us-gaap Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
P3Y8M
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
429000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1315000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1348000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1382000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
426000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
4900000
CY2021Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
499000
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
4401000
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1073000
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3328000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2843000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2966000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.82
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y10M24D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.42
CY2021Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
1000
CY2020Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
22000
us-gaap Investment Income Interest
InvestmentIncomeInterest
25000
us-gaap Investment Income Interest
InvestmentIncomeInterest
70000
CY2021Q3 us-gaap Interest Expense
InterestExpense
78000
CY2020Q3 us-gaap Interest Expense
InterestExpense
212000
us-gaap Interest Expense
InterestExpense
331000
us-gaap Interest Expense
InterestExpense
730000
CY2020Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
0
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-556000
CY2021Q3 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
44000
CY2020Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
1000
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
0
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
1000
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-121000
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-189000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-306000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1215000

Files In Submission

Name View Source Status
0000950170-21-004267-index-headers.html Edgar Link pending
0000950170-21-004267-index.html Edgar Link pending
0000950170-21-004267.txt Edgar Link pending
0000950170-21-004267-xbrl.zip Edgar Link pending
cmpx-20210930.htm Edgar Link pending
cmpx-20210930.xsd Edgar Link pending
cmpx-20210930_cal.xml Edgar Link unprocessable
cmpx-20210930_def.xml Edgar Link unprocessable
cmpx-20210930_htm.xml Edgar Link completed
cmpx-20210930_lab.xml Edgar Link unprocessable
cmpx-20210930_pre.xml Edgar Link unprocessable
cmpx-ex31_1.htm Edgar Link pending
cmpx-ex31_2.htm Edgar Link pending
cmpx-ex32_1.htm Edgar Link pending
cmpx-ex32_2.htm Edgar Link pending
cmpx-ex99_1.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
img118687774_0.jpg Edgar Link pending
img174977587_0.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending